NCT02326974 2026-04-17
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
14 trialsNCT01853748 2026-02-19
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02226276 2026-02-13
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT01494662 2026-01-23
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03032107 2025-01-27
A Study Of Pembrolizumab In Combination With Trastuzumab-DM1
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03530696 2024-08-13
T-DM1
University of Arizona
Phase 2 Completed
NCT03364348 2022-10-19
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
Stanford University
Phase 1 Completed
NCT02657343 2022-08-01
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01904903 2022-05-10
SAFE-HEaRt
Medstar Health Research Institute
Phase 2 Completed
NCT02562378 2022-02-23
THELMA
MedSIR
Phase 1 Completed
NCT02073487 2021-09-22
TEAL
The Methodist Hospital Research Institute
Phase 2 Completed
NCT02038010 2020-06-29
BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx
Northwestern University
Phase 1 Completed
NCT02318901 2019-10-21
PembroMab
Western Regional Medical Center
Phase 1/2 Terminated
NCT02658084 2019-04-17
Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer
University of Miami
Phase 1/2 Terminated